Nanobiotix (NASDAQ: NBTX) details March 2026 share count and voting power
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Nanobiotix S.A. reports its share capital and voting rights as of March 31, 2026. The company had 48,517,630 shares outstanding, corresponding to 50,165,132 theoretical voting rights and 50,143,014 exercisable voting rights. These figures are provided under French market transparency rules.
Positive
- None.
Negative
- None.
Key Figures
Shares outstanding: 48,517,630 shares
Theoretical voting rights: 50,165,132 voting rights
Exercisable voting rights: 50,143,014 voting rights
+1 more
4 metrics
Shares outstanding
48,517,630 shares
As of March 31, 2026
Theoretical voting rights
50,165,132 voting rights
Basis for threshold crossings, March 31, 2026
Exercisable voting rights
50,143,014 voting rights
Votes exercisable at shareholders’ meetings, March 31, 2026
ISIN code
FR0011341205
Euronext Paris listing identifier
Key Terms
theoretical voting rights, exercisable voting rights, threshold crossings, treasury shares, +1 more
5 terms
theoretical voting rights financial
"The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings."
Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.
exercisable voting rights financial
"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended."
Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.
threshold crossings financial
"The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings."
foreign private issuer regulatory
"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
FAQ
How many voting rights does Nanobiotix (NBTX) have as of March 31, 2026?
Nanobiotix reported 50,165,132 theoretical voting rights and 50,143,014 exercisable voting rights as of March 31, 2026. Theoretical rights include all shares with attached voting rights, while exercisable rights exclude shares where voting is suspended, such as treasury shares.
What is the difference between theoretical and exercisable voting rights at Nanobiotix?
The theoretical voting rights (50,165,132) include all shares with attached voting rights, even if suspended. The exercisable voting rights (50,143,014) exclude shares with suspended rights, such as treasury shares, and reflect votes that can actually be cast at shareholder meetings.
Which regulations govern Nanobiotix’s disclosure of voting rights?
The disclosure is made in accordance with article L.233-8 II of the French Commercial Code and article 223-16 of the AMF General Regulation. These rules require companies to regularly publish updated information on share capital and voting rights for market transparency.